Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by scroll4factson Mar 27, 2016 11:49pm
165 Views
Post# 24703831

RE:Q1........By the Numbers

RE:Q1........By the Numbers
In your little projection I guess you took half  the Q4 2015 product sales. Somewhat pessimistic in my opinion. The CDN$ has been weaker, sales force increased and, as far as I know, the PAP has not been modified. Why would this pharma have 2 buy recommendations from analysts with $8+ targets?  I think Q1 could be profitable and if not,  it would be related to P2 trial and restructuring costs.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities